Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230013/S027

EVOQUE Tricuspid Valve Replacement System

Edwards Lifesciences, LLC · Decision date Sep 16, 2026

MEDTECHLEDGER EXPLANATIONP230013/S027

What did the FDA approve?

The FDA record for P230013/S027, dated 2026-09-16, is a supplement to the EVOQUE Tricuspid Valve Replacement System approval held by Edwards Lifesciences, LLC. It was filed on the Normal 180 Day Track under the labeling-change reason covering indications, instructions, shelf life, or tradename. The stated purpose is to approve modifications to the Instructions for Use, specifically adding internal jugular venous access and revising the sizing table.

Because the identifier links S027 to the original P230013 approval, this is a change to the cleared labeling of an existing device, not a new approval of the whole system. The record gives no detail on the revised sizing criteria, access technique, or any supporting data, and the statement's stated purpose is not independent proof of safety or clinical effectiveness.

FDA approval order statement

Approval for various modifications to the Instructions for Use, including the addition of internal jugular venous access and revision of the sizing table.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Sep 16, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230013/S027
Regulatory pathway
PMA supplement
Product code
NPW
Decision code
APPR
Decision date
Sep 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.

Product code
NPW
FDA device class
3

For the original device and its historical approval scope, see PMA P230013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230013 · Original PMA

    Edwards EVOQUE Tricuspid Valve Replacement System

  2. P230013/S027 received

    Application receipt date recorded by FDA.

  3. P230013/S027 · FDA decision

    Normal 180 Day Track

  4. P230013/S029 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  5. P230013/S033 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  6. P230013/S034 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)

Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230013

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records